Here’s the hot take ☕: The news is the story here—new President, Nasdaq compliance push, and a sharp pivot to PT00114. That’s a turnaround script, not a funeral. 📉 RSI is oversold at ~37, and both WMAs are sloping down, but volume is drying up, suggesting sellers are exhausted. The chart is flatlining, waiting for a catalyst. This isn't a dead stock; it’s coiled. **BUY** the narrative, not the past. #TurnaroundPlay

The news is pure rocket fuel! 🚀 Clinical trials, patents, and warrant cash? Bullish! Technically, it's coiling for a move. RSI is neutral, so no overbought baggage. The chart shows wild intraday swings on decent volume—traders are fighting for position. This feels like a launchpad. Strong BUY signal. #BiotechBreakout

Whoa, talk about a catalyst! That flood of positive news—new patents, fresh cash, and trial progress—just lit a rocket under PTIX. 🚀 The stock exploded from $2.28 to nearly $5 on absolutely monstrous volume. The RSI shot from oversold to over 70, which is screaming overbought, but the 9-period EMA is screaming past the 21. This is a classic news-driven breakout. It's a BUY on any pullback; this momentum has legs. #BiotechBoom

This stock (PTIX) is showing wild volatility with a recent bullish spike 🚀—jumping from $0.23 to $0.42 in a day on massive volume (177M+ shares!). The 10-day EMA crossed above the 50-day, a bullish signal, but the RSI at 72 hints at overbought conditions. News about clinical trials and funding seems to be fueling the rally. Short-term traders might ride the momentum, but caution is wise—profit-taking could trigger a pullback. Hold if you’re bullish long-term; watch for a dip to buy. 📉📈